In this double-blind trial , we randomly assigned etonogestrel implant users reporting 7 consecutive days or more of bothersome bleeding to receive 14 pills of study drug ( 150 microgram levonorgestrel and 30 microgram ethinyl estradiol combined OCPs ) or an identical-appearing placebo .